Kennedy Ferruggia, Associate Editor

Research reveals associations between body composition, fitness, and mental health in children, highlighting the impact of obesity on anxiety and depression.

A new oral PCSK9 inhibitor, enlicitide, shows promise in significantly lowering LDL cholesterol, offering hope for hypercholesterolemia management and cardiovascular health.

Abemaciclib significantly enhances overall survival in high-risk HR+, HER2- early breast cancer, establishing a new standard of care.

Vaccination is vital for adults with heart disease to prevent severe respiratory illnesses like RSV, influenza, and COVID-19, enhancing overall health outcomes.

An international BMJ panel recommended broader use of SGLT-2 inhibitors and GLP-1 receptor agonists.

The FDA has approved a ready-to-use long-acting injectable formulation that is administered every 3 months as a treatment for advanced prostate cancer.

Employers are facing higher costs and employees higher premiums as 340B’s growth drives lost rebates and rising drug prices.

An immunomodulatory nanoparticle called Agg-CLNP has been shown to effectively prevent disease onset for rheumatoid arthritis (RA).

Generic liraglutide injection is the first GLP-1 indicated for weight loss.

COVID-19 vaccination significantly reduces the risk of asthma and other airway inflammatory diseases, offering vital protection against respiratory complications.

Orforglipron is an effective treatment, leading to significant body weight reduction and improved glycemic control.

Increasing dietary potassium, such as from bananas, may lower blood pressure more effectively than reducing sodium alone.

The sensor detects acetone levels in the breath to indicate diabetes.

Expert emphasizes the need for stronger transparency and patient definitions in the 340B program.

A novel shingles vaccine candidate demonstrated positive top-line results of antibody and CD4⁺ T-cell vaccine responses.

A better understanding of the activation of amylin receptors is a step forward for developing new drugs.

RSV causes a significant burden of acute respiratory infections in older adults.

Evolocumab is now indicated for adults at increased risk for major adverse cardiovascular events (MACE).

Individuals with bipolar disorder are at nearly a 2-fold higher risk of heart failure, which is marked as the main cause of premature cardiovascular mortality.

RSVpreF was well tolerated in nonpregnant and pregnant individuals aged 18 years and older.

The oral glucagon-like peptide agonist-1 met its primary end point and all secondary end points in a randomized, double-blind, placebo-controlled clinical trial for weight management.

The FDA approves donidalorsen, the first RNA-targeted therapy for hereditary angioedema, offering significant attack reduction and convenient administration.

New research uncovers complex inflammatory pathways driving asthma flare-ups in children, highlighting the need for personalized treatment strategies.

Simplifying complex information through illustrations and storytelling helps patients feel that managing their condition is achievable.

An expert shares how 340B puts independent pharmacies at a competitive disadvantage.

New research uncovers a pathway linking diabetes and heightened blood clot risks, paving the way for innovative treatments to prevent cardiovascular complications.

Signos CGM empowers users to manage weight effectively through personalized insights and real-time glucose tracking.

Long-term obesity triggers aging biomarkers in young adults, linking excess weight to accelerated biological aging and chronic health risks.

FDA approves semaglutide for treating MASH, offering new hope for affected individuals.

RSV vaccination rates among older adults remain low despite new vaccines, highlighting disparities in uptake and the need for targeted outreach.